Publications Repository

Publications Repository

View Item 
  •   Home
  • ICR Divisions
  • Cancer Biology
  • View Item
  • Home
  • ICR Divisions
  • Cancer Biology
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma.

Thumbnail
View/Open
Accepted version (427.9Kb)
ICR Author
Harrington, Kevin
Author
Lee, AW
Ng, WT
Pan, JJ
Chiang, C-L
Poh, SS
Choi, HC
Ahn, YC
AlHussain, H
Corry, J
Grau, C
Grégoire, V
Harrington, KJ
Hu, CS
Kwong, DL
Langendijk, JA
Le, QT
Lee, NY
Lin, JC
Lu, TX
Mendenhall, WM
O'Sullivan, B
Ozyar, E
Peters, LJ
Rosenthal, DI
Sanguineti, G
Soong, YL
Tao, Y
Yom, SS
Wee, JT
Type
Journal Article
Metadata
Show full item record
Abstract
<h4>Purpose</h4>The treatment of nasopharyngeal carcinoma requires high radiation doses. The balance of the risks of local recurrence owing to inadequate tumor coverage versus the potential damage to the adjacent organs at risk (OARs) is of critical importance. With advancements in technology, high target conformality is possible. Nonetheless, to achieve the best possible dose distribution, optimal setting of dose targets and dose prioritization for tumor volumes and various OARs is fundamental. Radiation doses should always be guided by the As Low As Reasonably Practicable principle. There are marked variations in practice. This study aimed to develop a guideline to serve as a global practical reference.<h4>Methods and materials</h4>A literature search on dose tolerances and normal-tissue complications after treatment for nasopharyngeal carcinoma was conducted. In addition, published guidelines and protocols on dose prioritization and constraints were reviewed. A text document and preliminary set of variants was circulated to a panel of international experts with publications or extensive experience in the field. An anonymized voting process was conducted to rank the proposed variants. A summary of the initial voting and different opinions expressed by members were then recirculated to the whole panel for review and reconsideration. Based on the comments of the panel, a refined second proposal was recirculated to the same panel. The current guideline was based on majority voting after repeated iteration for final agreement.<h4>Results</h4>Variation in opinion among international experts was repeatedly iterated to develop a guideline describing appropriate dose prioritization and constraints. The percentage of final agreement on the recommended parameters and alternative views is shown. The rationale for the recommendations and the limitations of current evidence are discussed.<h4>Conclusions</h4>Through this comprehensive review of available evidence and interactive exchange of vast experience by international experts, a guideline was developed to provide a practical reference for setting dose prioritization and acceptance criteria for tumor volumes and OARs. The final decision on the treatment prescription should be based on the individual clinical situation and the patient's acceptance of optimal balance of risk.
URL
https://repository.icr.ac.uk/handle/internal/4447
Collections
  • Cancer Biology
  • Radiotherapy and Imaging
Licenseref URL
http://www.rioxx.net/licenses/all-rights-reserved
Version
AM
Version of record
10.1016/j.ijrobp.2019.06.2540
Subject
Humans
Nasopharyngeal Neoplasms
Neoplasm Recurrence, Local
Radiation Injuries
Radiotherapy Dosage
Radiotherapy Planning, Computer-Assisted
Tumor Burden
International Cooperation
Delphi Technique
Radiotherapy, Intensity-Modulated
Organs at Risk
GRADE Approach
Nasopharyngeal Carcinoma
Research team
Targeted Therapy
Language
eng
Date accepted
2019-06-25
Citation
International journal of radiation oncology, biology, physics, 2019, 105 (3), pp. 567 - 580

Browse

All of ICR repositoryICR DivisionsIssue dateAuthorsTitlesSubjectsThis collectionIssue dateAuthorsTitlesSubjects

Statistics

Most popular itemsStatistics by countryMost popular authors
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.